Skip to content
Research Article Open access CC BY 4.0

In Silico Studies on the Phytochemicals from Aframomum melegueta Leaves against Key Enzymes as Anti-Alzheimer’s Disease Target

G. Oluwadahunsi, S. T. Akinwotu, T. M. Fadipe, O. P. Akintoye, T. J. Omoyajowo, E. T. Ologuntere, Z. Abdullah

International Journal of Biochemistry Research & Review · pp. 39–53 · Published 25 Feb 2022

10.9734/ijbcrr/2022/v31i130299

Abstract

Traditional medicine has been practiced for ages across the world using plants as a memory booster and in the treatment of neurodegenerative diseases such as dementia and amnesia. The tau, amyloid hypothesis and neuroinflammation hypothesis are major partakers in a combinational approach in the development of therapy against Alzheimer’s disease (AD), Acetyl and butyryl cholinesterases inhibitors have been investigated in clinical trials of AD for a very long time. This research involved an in-silico approach to study the interactions of phytochemicals in Aframomum melegueta leaves with some enzymes that have been reported in the literature which contribute to neuronal death and memory loss associated in AD. In these studies, Curcumin and Lilacin are shown to have a higher glide score than the co-crystallized ligands of either Acetylcholinesterase, Butyrylcholinesterase or GSK-3β, they also have higher glide scores than AChE inhibitor Rivastigmine. The ADMET/tox properties of our lead compounds (curcumin and lilacin) ranked them as good candidates for AD drug development, as well as possess the highest docking scores against acetylcholinesterase, butyrylcholinesterase and GSK-3 beta suggesting potent compounds in Alzheimer’s disease therapy. The pharmacokinetics studies also showed that curcumin and lilacin would pass through the blood brain barrier into the brain. This work is in line with recent multi-dimensional approach in drug development in that a single compound might possess many active groups which can activate/inhibit more than one protein without any toxic effect.

AChE BChE GSK-3β Alzheimer’s disease molecular docking curcumin; lilacin

References (23)

  1. 1 The amyloid hypothesis of Alzheimer's disease at 25 years [DOI]
  2. 2 Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments [DOI]
  3. 3 Role of Genes and Environments for Explaining Alzheimer Disease [DOI]
  4. 4 The GSK3 hypothesis of Alzheimer’s disease [DOI]
  5. 5 Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution [DOI]
  6. 6 Current and Future Treatments in Alzheimer Disease: An Update [DOI]
  7. 7 Computational methods for biomolecular docking [DOI]
  8. 8 Cholinesterase inhibitors as Alzheimer's therapeutics (Review) [DOI]
  9. 9 A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease [DOI]
  10. 10 Molecular Docking Using Chimera and Autodock Vina Software for Nonbioinformaticians [DOI]
  11. 11 Combination Drug Therapy for the Management of Alzheimer’s Disease [DOI]
  12. 12 Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease [DOI]
  13. 13 Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery [DOI]
  14. 14 An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease [DOI]
  15. 15 Rivastigmine in the treatment of patients with Alzheimer's disease [DOI]
  16. 16 Traditional Oriental Medicines and Alzheimer’s Disease [DOI]
  17. 17 Computational studies by molecular docking of some antiviral drugs with COVID-19 receptors are an approach to medication for COVID-19 [DOI]
  18. 18 Chemical Constituents of the Leaf, Stem, Root and Seed Essential Oils of Aframomum melegueta (K. Schum) from South West Nigeria [DOI]
  19. 19 Commercialization of Aframomum spp. in Africa: a Systematic Review of Literature and Supporting Botanical Vouchers [DOI]
  20. 20 Assessment of in-vitro Antioxidant/Enzymes Inhibitory Potentials of Aframomum melegueta [Roscoe] K. Schum (Grains of Paradise) Leaf, Stem Bark, Seed Bark and Seed Extracts [DOI]
  21. 21 Neuropsychiatric Disease and Treatment [DOI]
  22. 22 Journal of Computer-Aided Molecular Design [DOI]
  23. 23 International Research Journal of Pure and Applied Chemistry [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

7

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.